Literature DB >> 23568223

Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study.

Roderick C Deaño1, Cherylanne Glassner-Kolmin, Melvyn Rubenfire, Adaani Frost, Scott Visovatti, Vallerie V McLaughlin, Mardi Gomberg-Maitland.   

Abstract

IMPORTANCE: Pulmonary hypertension (PH) is a fatal disease. Although the prognosis of pulmonary arterial hypertension (PAH) has improved with targeted therapies, the outcome is dependent on early detection and an accurate diagnosis.
OBJECTIVE: To determine the accuracy of PH diagnoses in patients referred to PH centers and the frequency of PAH-specific medication use despite an uncertain or incorrect diagnosis.
DESIGN: Multicenter, descriptive, cross-sectional study. During a 10-month period in 2010 and 2011, data on newly referred patients were collected and entered into a secure Internet database.
SETTING: Three large tertiary PH centers. PARTICIPANTS: One hundred forty consecutive patients newly referred to PH centers were invited to participate, and all consented to do so.
RESULTS: Of 140 patients referred with a mean age of 56 years, 95 (68%) were referred by cardiologists or pulmonologists and 86 (61%) had disease classified as World Health Organization functional class III or IV. Fifty-six of the prereferral diagnoses (40%) were PAH, 42 (30%) unknown, and 22 (16%) PH secondary to lung disease or hypoxia. Of the 98 patients who received a definitive diagnosis before referral, 32 (33%) received a misdiagnosis. Fifty-nine patients underwent catheterization of the right and/or left side of the heart for the first time at the tertiary center. Of the 38 patients who underwent catheterization of the right side alone, 14 (37%) received a different diagnosis after undergoing the procedure; of the 21 patients who underwent catheterization of both sides of the heart, 11 (52%) received a different diagnosis after undergoing the procedures. Forty-two patients (30%) had started receiving PAH-specific medications before referral, with 24 of the prescriptions (57%) contrary to published guidelines. CONCLUSIONS AND RELEVANCE: Patients referred to PH centers for diagnosis and treatment are often referred late (with functional class III or IV disease), receive misdiagnoses, and are inappropriately prescribed medications. A reevaluation of educational efforts is required to improve awareness and the care and outcome of patients diagnosed as having PH.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568223     DOI: 10.1001/jamainternmed.2013.319

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  54 in total

1.  Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension.

Authors:  Anna R Hemnes; Aaron W Trammell; Stephen L Archer; Stuart Rich; Chang Yu; Hui Nian; Niki Penner; Mitchell Funke; Lisa Wheeler; Ivan M Robbins; Eric D Austin; John H Newman; James West
Journal:  Circulation       Date:  2014-10-31       Impact factor: 29.690

Review 2.  Pulmonary Hypertension Due to Left Heart Disease: an Update.

Authors:  Mandar A Aras; Mitchell A Psotka; Teresa De Marco
Journal:  Curr Cardiol Rep       Date:  2019-05-27       Impact factor: 2.931

3.  Learning a Comorbidity-Driven Taxonomy of Pediatric Pulmonary Hypertension.

Authors:  Mei-Sing Ong; Mary P Mullen; Eric D Austin; Peter Szolovits; Marc D Natter; Alon Geva; Tianxi Cai; Sek Won Kong; Kenneth D Mandl
Journal:  Circ Res       Date:  2017-06-13       Impact factor: 17.367

4.  The heterogeneity of clinical practice patterns among an international cohort of pulmonary arterial hypertension experts.

Authors:  John J Ryan; Ghazwan Butrous; Bradley A Maron
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

5.  Response.

Authors:  Kari R Gillmeyer; Ming-Ming Lee; Alissa P Link; Elizabeth S Klings; Seppo T Rinne; Renda Soylemez Wiener
Journal:  Chest       Date:  2019-05       Impact factor: 9.410

6.  Multisystem Healthcare Use among U.S. Veterans with Pulmonary Hypertension.

Authors:  Kari R Gillmeyer; Kyung M Lee; Qing Shao; Donald R Miller; Bradley A Maron; Elizabeth S Klings; Seppo T Rinne; Renda Soylemez Wiener
Journal:  Ann Am Thorac Soc       Date:  2019-08

Review 7.  Translational Advances in the Field of Pulmonary Hypertension. Focusing on Developmental Origins and Disease Inception for the Prevention of Pulmonary Hypertension.

Authors:  Bradley A Maron; Steven H Abman
Journal:  Am J Respir Crit Care Med       Date:  2017-02-01       Impact factor: 21.405

8.  Accuracy of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data: A Systematic Review.

Authors:  Kari R Gillmeyer; Ming-Ming Lee; Alissa P Link; Elizabeth S Klings; Seppo T Rinne; Renda Soylemez Wiener
Journal:  Chest       Date:  2018-11-22       Impact factor: 9.410

9.  Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers.

Authors:  Aaron W Trammell; Meredith E Pugh; John H Newman; Anna R Hemnes; Ivan M Robbins
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

Review 10.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.